^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    GEN1160

    i
    Other names: GEN1160, PRO1160, GEN-1160, PRO-1160, PRO 1160, GEN 1160
    Associations

    News

    Trials
    Company:
    Genmab
    Drug class:
    Topoisomerase I inhibitor, CD70-targeted antibody-drug conjugate
    Related drugs:
    Associations

    News

    Trials
    22d
    Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) (PRO1160-001) (clinicaltrials.gov)
    P1/2, N=42, Terminated, Genmab | N=110 --> 42 | Trial completion date: Dec 2026 --> Nov 2025 | Recruiting --> Terminated | Trial primary completion date: Sep 2026 --> Nov 2025; Genmab has decided to discontinue the clinical development of GEN1160 due to slow enrolment
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date
    |
    GEN1160
    2years
    Phase 1/2 study of PRO1160, a CD70-directed antibody-drug conjugate, in patients with advanced solid tumors and hematologic malignancies (SITC 2023)
    PK, immunogenicity, and antitumor activity will also be evaluated. The study is currently enrolling at sites in the US, with future enrollment in China planned.
    Clinical • P1/2 data • Metastases
    |
    CD70 (CD70 Molecule)
    |
    GEN1160
    over3years
    PRO1160, a novel CD70-directed antibody-drug conjugate, demonstrates robust anti-tumor activity in mouse models of renal cell carcinoma and non-Hodgkin lymphoma (AACR 2022)
    PRO1160 has the potential for an expanded therapeutic index. PRO1160 is being developed for the potential treatment of patients with CD70-expressing hematologic and solid tumor cancers.
    Preclinical
    |
    CD70 (CD70 Molecule)
    |
    CD70 expression
    |
    GEN1160